Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

When was the last time you thought about your lungs unless you were short of breath or down with a cold? Most of us take our lungs for granted, but these spongy, hard-working organs do a lot more than ...

Common symptoms of pneumonia include a persistent cough, difficulty breathing, high fever, chest pain, body aches, extreme ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Also assessed were effects on interleukin (IL)-8 levels, lung function ... Conclusion: Treatment with NAC 1200 mg/day improved biological markers and clinical outcomes in patients with COPD ...

17, 2025 — A clinical trial conducted in a neonatal intensive care unit has identified a new treatment ... disease (COPD), and ... How a New Gut Microbe Drives the Gut-Lung Axis Dec. 19, 2024 ...

With my relationship and mattress access on the line, I tried sleeping with the Snorinator for a month to see if it could ...

PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...